131740-09-5 | Flavopiridol Hydrochloride

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$19.00	$14.00
5mg	98%	in stock	$55.00	$38.00
10mg	98%	in stock	$81.00	$57.00
25mg	≥95%	in stock	$184.00	$129.00
50mg	98%	in stock	$271.00	$190.00

Description

• Catalog Number: AB50329
• Chemical Name: Flavopiridol Hydrochloride
• CAS Number: 131740-09-5
• Molecular Formula: C21H21Cl2NO5
• Molecular Weight: 438.3011
• MDL Number: MFCD26792554
• SMILES: CN1CC[C@@H]([C@@H](C1)O)c1c(O)cc(c2c1oc(cc2=O)c1ccccc1Cl)O.Cl

Computed Properties

• Complexity: 628
• Covalently-Bonded Unit Count: 2
• Defined Atom Stereocenter Count: 2
• Heavy Atom Count: 29
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 2

Literature

• Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells.

  BMC pharmacology & toxicology 20130101

• Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

  Haematologica 20121101

• A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261.

  Gynecologic oncology 20121001

• CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.

  Cancer research 20120815

• ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.

  Blood 20120809

• Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features.

  Leukemia 20120601

• Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.

  Cancer chemotherapy and pharmacology 20120601

• The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120501

• Delayed cell cycle pathway modulation facilitates recovery after spinal cord injury.

  Cell cycle (Georgetown, Tex.) 20120501

• A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.

  Investigational new drugs 20120401

• Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development.

  Cell cycle (Georgetown, Tex.) 20120315

• CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol.

  International journal of cancer 20120301

• Hematologic improvement after flavopiridol treatment of pentostatin and rituximab refractory hairy cell leukemia.

  Leukemia & lymphoma 20120301

• Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach.

  Haematologica 20120301

• A mathematical model of cell cycle effects in gastric cancer chemotherapy.

  Bulletin of mathematical biology 20120101

• GSK3β inhibition is involved in the neuroprotective effects of cyclin-dependent kinase inhibitors in neurons.

  Pharmacological research 20120101

• Cyclin-dependent kinase 9 activity regulates neutrophil spontaneous apoptosis.

  PloS one 20120101

• Characterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell death.

  PloS one 20120101

• Preclinical study of treatment response in HCT-116 cells and xenografts with (1) H-decoupled (31) P MRS.

  NMR in biomedicine 20111101

• A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors.

  Investigational new drugs 20111001

• Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia.

  Leukemia & lymphoma 20111001

• The BH3-only protein Noxa is stimulated during apoptosis of chronic lymphocytic leukemia cells triggered by M2YN, a new plant-derived extract.

  International journal of oncology 20111001

• Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies.

  Expert review of hematology 20111001

• Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.

  Leukemia 20110901

• Acute myeloid leukaemia: optimal management and recent developments.

  Drugs 20110820

• Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis.

  Cancer biology & therapy 20110815

• [Present status and perspective of targeted therapy for B-cell lymphoma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20110801

• Novel purine-based fluoroaryl-1,2,3-triazoles as neuroprotecting agents: synthesis, neuronal cell culture investigations, and CDK5 docking studies.

  Bioorganic & medicinal chemistry letters 20110701

• Leukemia cutis in association With Grover's disease.

  The American Journal of dermatopathology 20110601

• Constitutive Smad linker phosphorylation in melanoma: a mechanism of resistance to transforming growth factor-β-mediated growth inhibition.

  Pigment cell & melanoma research 20110601

• Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110515

• Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.

  Blood 20110324

• Flavopiridol inhibits lipopolysaccharide-induced TNF-α production through inactivation of nuclear factor-κB and mitogen-activated protein kinases in the MyD88-dependent pathway.

  Microbiology and immunology 20110301

• Homology modeling, molecular dynamic simulation and docking studies of cyclin dependent kinase 1.

  Journal of molecular modeling 20110201

• Flavopiridol protects against inflammation by attenuating leukocyte-endothelial interaction via inhibition of cyclin-dependent kinase 9.

  Arteriosclerosis, thrombosis, and vascular biology 20110201

• Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells.

  Blood 20110113

• Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells.

  Leukemia 20110101

• The CDK9/cyclin T1 subunits of P-TEFb in mouse oocytes and preimplantation embryos: a possible role in embryonic genome activation.

  BMC developmental biology 20110101

• CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation.

  Molecular endocrinology (Baltimore, Md.) 20101201

• Assaying pharmacodynamic endpoints with targeted therapy: flavopiridol and 17AAG induced dephosphorylation of histone H1.5 in acute myeloid leukemia.

  Proteomics 20101201

• Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53.

  Molecular cancer therapeutics 20101201

• Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.

  Cancer biology & therapy 20101101

• A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.

  Cancer chemotherapy and pharmacology 20101101

• Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy.

  Mini reviews in medicinal chemistry 20101001

• [Synergism of antitumor effects on ovarian carcinoma using autocatalytic caspase-3 combined with flavopiridol].

  Zhonghua fu chan ke za zhi 20101001

• P-TEFb kinase complex phosphorylates histone H1 to regulate expression of cellular and HIV-1 genes.

  The Journal of biological chemistry 20100924

• Live-cell imaging RNAi screen identifies PP2A-B55alpha and importin-beta1 as key mitotic exit regulators in human cells.

  Nature cell biology 20100901

• A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer.

  American journal of clinical oncology 20100801

• Human chorionic gonadotropin up-regulates expression of myeloid cell leukemia-1 protein in human granulosa-lutein cells: implication of corpus luteum rescue and ovarian hyperstimulation syndrome.

  The Journal of clinical endocrinology and metabolism 20100801

• Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.

  Molecular cancer therapeutics 20100801

• Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents.

  Cancer chemotherapy and pharmacology 20100701

• Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

  Leukemia research 20100701

• T-loop phosphorylated Cdk9 localizes to nuclear speckle domains which may serve as sites of active P-TEFb function and exchange between the Brd4 and 7SK/HEXIM1 regulatory complexes.

  Journal of cellular physiology 20100701

• Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment.

  Biochemical pharmacology 20100701

• Sequential flavopiridol, mitoxantrone and cytosine arabinoside for newly diagnosed poor risk acute myeloid leukemia. What to do next?

  Leukemia research 20100701

• Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.

  Haematologica 20100701

• Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.

  The Journal of pharmacology and experimental therapeutics 20100601

• Recombinant Leishmania mexicana CRK3:CYCA has protein kinase activity in the absence of phosphorylation on the T-loop residue Thr178.

  Molecular and biochemical parasitology 20100601

• Specificity in the interaction of natural products with their target proteins--a biochemical and structural insight.

  Mini reviews in medicinal chemistry 20100601

• A combination of cisplatin-eluting gelatin microspheres and flavopiridol enhances anti-tumour effects in a rabbit VX2 liver tumour model.

  The British journal of radiology 20100501

• Chemotherapeutic drugs inhibit ribosome biogenesis at various levels.

  The Journal of biological chemistry 20100416

• Dysoxylum binectariferum Hook.f (Meliaceae), a rich source of rohitukine.

  Fitoterapia 20100301

• Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100120

• New agents in chronic lymphocytic leukemia.

  Current hematologic malignancy reports 20100101

• The binding of flavopiridol to blood serum albumin.

  Chirality 20100101

• Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.

  PloS one 20100101

• Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen.

  BMC cancer 20100101

• Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091210

• Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20091201

• Misguided transcriptional elongation causes mixed lineage leukemia.

  PLoS biology 20091101

• Flavopiridol reduces the impedance of neural prostheses in vivo without affecting recording quality.

  Journal of neuroscience methods 20091015

• SKIP interacts with c-Myc and Menin to promote HIV-1 Tat transactivation.

  Molecular cell 20091009

• Emerging therapies for patients with advanced chronic lymphocytic leukaemia.

  Blood reviews 20090901

• New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines.

  Current oncology reports 20090901

• Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication.

  Chembiochem : a European journal of chemical biology 20090817

• CDK9 directs H2B monoubiquitination and controls replication-dependent histone mRNA 3'-end processing.

  EMBO reports 20090801

• The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity.

  Haematologica 20090701

• Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.

  Blood 20090507

• The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice.

  Drug metabolism and disposition: the biological fate of chemicals 20090501

• Camptothecin releases P-TEFb from the inactive 7SK snRNP complex.

  Cell cycle (Georgetown, Tex.) 20090415

• Transforming growth factor-{beta}-inducible phosphorylation of Smad3.

  The Journal of biological chemistry 20090410

• Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.

  Blood 20090319

• Targeting MET transcription as a therapeutic strategy in multiple myeloma.

  Cancer chemotherapy and pharmacology 20090301

• Noxa upregulation is associated with apoptosis of chronic lymphocytic leukemia cells induced by hyperforin but not flavopiridol.

  Leukemia 20090301

• Role of the HIV-1 positive elongation factor P-TEFb and inhibitors thereof.

  Mini reviews in medicinal chemistry 20090301

• Retinoblastoma tumor suppressor gene expression determines the response to sequential flavopiridol and doxorubicin treatment in small-cell lung carcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090215

• A novel liposomal formulation of flavopiridol.

  International journal of pharmaceutics 20090105

• Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy.

  The International journal of biological markers 20090101

• A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer.

  Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 20090101

• Flavopiridol in chronic lymphocytic leukemia: a concise review.

  Clinical lymphoma & myeloma 20090101

• Future research directions for the treatment of AML.

  Clinical advances in hematology & oncology : H&O 20081101

• Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.

  Therapeutic drug monitoring 20081001

• Combinatorial antileukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide 2-(2,4-difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and flavopiridol.

  Molecular pharmacology 20080901

• Flavopiridol potentiates the cytotoxic effects of radiation in radioresistant tumor cells in which p53 is mutated or Bcl-2 is overexpressed.

  International journal of radiation oncology, biology, physics 20080801

• Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies.

  Clinical lymphoma & myeloma 20080801

• The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation.

  The EMBO journal 20080709

• Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080601

• Flavopiridol-induced iNOS downregulation during apoptosis of chronic lymphocytic leukemia cells is caspase-dependent.

  Leukemia research 20080501

• Delayed combinatorial treatment with flavopiridol and minocycline provides longer term protection for neuronal soma but not dendrites following global ischemia.

  Journal of neurochemistry 20080501

• Flavopiridol suppresses tumor necrosis factor-induced activation of activator protein-1, c-Jun N-terminal kinase, p38 mitogen-activated protein kinase (MAPK), p44/p42 MAPK, and Akt, inhibits expression of antiapoptotic gene products, and enhances apoptosis through cytochrome c release and caspase activation in human myeloid cells.

  Molecular pharmacology 20080501

• Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer.

  Clinical lung cancer 20080501

• Flavopiridol displays preclinical activity in acute lymphoblastic leukemia.

  Pediatric blood & cancer 20080401

• The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.

  Cancer research 20080401

• Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium.

  Blood 20080315

• P-TEFb inhibitors interfere with activation of p53 by DNA-damaging agents.

  Oncogene 20080221

• Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors.

  Journal of immunology (Baltimore, Md. : 1950) 20080201

• Transcription-dependent gene looping of the HIV-1 provirus is dictated by recognition of pre-mRNA processing signals.

  Molecular cell 20080118

• Rhabdoid tumor growth is inhibited by flavopiridol.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080115

• The functional role of an interleukin 6-inducible CDK9.STAT3 complex in human gamma-fibrinogen gene expression.

  The Journal of biological chemistry 20071221

• Lack of association between common polymorphisms in UGT1A9 and gene expression and activity.

  Drug metabolism and disposition: the biological fate of chemicals 20071201

• Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells.

  Molecular cancer therapeutics 20071201

• Cell cycle activation contributes to post-mitotic cell death and secondary damage after spinal cord injury.

  Brain : a journal of neurology 20071101

• Flavopiridol in the treatment of chronic lymphocytic leukemia.

  Current opinion in oncology 20071101

• [Therapeutic effect of flavopiridol, a small molecular cyclin-dependent kinase inhibitor, in human ovarian carcinoma].

  Zhonghua fu chan ke za zhi 20071101

• Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071001

• Cyclin-dependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug-resistant osteosarcoma and Ewing's family tumor cells.

  International journal of cancer 20070915

• Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia.

  Best practice & research. Clinical haematology 20070901

• Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIPL.

  Cancer chemotherapy and pharmacology 20070801

• UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers.

  Pharmacogenetics and genomics 20070801

• Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070801

• [DMF induces apoptosis in human androgen-independent prostate cancer PC3 cells in vitro].

  Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20070501

• [Research on cyclin-dependent kinase inhibitors: state of the art and perspective].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20070501

• In vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia.

  British journal of haematology 20070401

• Levels of p27(kip1) determine Aplidin sensitivity.

  Molecular cancer therapeutics 20070401

• Small molecule inhibitors of Stat3 signaling pathway.

  Current cancer drug targets 20070201

• Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.

  Molecular cancer therapeutics 20070201

• Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with acute myelogenous leukemia.

  Hematology (Amsterdam, Netherlands) 20070201

• Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.

  Blood 20070115

• Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues.

  Bioorganic & medicinal chemistry 20070115

• Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex.

  Retrovirology 20070101

• Bioactivity of glycogen phosphorylase inhibitors that bind to the purine nucleoside site.

  Bioorganic & medicinal chemistry 20061201

• Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.

  Cancer research 20061201

• A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.

  Cancer research 20061115

• Induction of apoptosis and down regulation of cell cycle proteins in mantle cell lymphoma by flavopiridol treatment.

  Leukemia research 20061101

• Antisense inhibition of cyclin D1 expression is equivalent to flavopiridol for radiosensitization of zebrafish embryos.

  International journal of radiation oncology, biology, physics 20061001

• Sequential combinations of flavopiridol and docetaxel inhibit prostate tumors, induce apoptosis, and decrease angiogenesis in the Ggamma/T-15 transgenic mouse model of prostate cancer.

  The Prostate 20061001

• Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil.

  Acta pharmacologica Sinica 20061001

• Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells.

  Cancer research 20060915

• Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection.

  Cell death and differentiation 20060901

• Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells.

  Cancer research 20060901

• The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis.

  International journal of molecular medicine 20060801

• Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20060801

• Alvocidib (Flavopiridol) suppresses tumor growth in SCID mice with human esophageal cancer xenografts without inducing apoptosis.

  Surgical oncology 20060801

• MicroRNAs in leukemia.

  Clinical advances in hematology & oncology : H&O 20060801

• A phase I study of flavopiridol and docetaxel.

  Investigational new drugs 20060701

• Cyclin dependent kinase inhibitors prevent apoptosis of postmitotic mouse motoneurons.

  Life sciences 20060627

• Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells.

  Cancer research 20060601

• Sequential combination of flavopiridol and docetaxel reduces the levels of X-linked inhibitor of apoptosis and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells.

  Molecular cancer therapeutics 20060501

• The reversibility of mitotic exit in vertebrate cells.

  Nature 20060413

• The first metal-based paullone derivative with high antiproliferative activity in vitro.

  Inorganic chemistry 20060306

• Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points.

  Haematologica 20060301

• Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2.

  Molecular pharmacology 20060101

• Radiation sensitivity of GL261 murine glioma model and enhanced radiation response by flavopiridol.

  Cell cycle (Georgetown, Tex.) 20060101

• Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein.

  Expert opinion on investigational drugs 20060101

• Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy.

  Molecular cancer therapeutics 20060101

• A common protein fold topology shared by flavonoid biosynthetic enzymes and therapeutic targets.

  Journal of natural products 20060101

• Effects of PRIMA-1 on wild-type L1210 cells expressing mutant p53 and drug-resistant L1210 cells lacking expression of p53: necrosis vs. apoptosis.

  Anticancer research 20060101

• Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics.

  Current pharmaceutical design 20060101

• Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051220

• Indirubin-3'-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication.

  AIDS (London, England) 20051202

• Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051201

• Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity.

  Leukemia research 20051101

• Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.

  Blood 20051001

• Role of the cell cycle in the pathobiology of central nervous system trauma.

  Cell cycle (Georgetown, Tex.) 20050901

• Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050815

• A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study.

  Gynecologic oncology 20050801

• A study of cytotoxic synergy of UCN-01 and flavopiridol in syngeneic pair of cell lines.

  Investigational new drugs 20050801

• A noninvasive approach for assessing tumor hypoxia in xenografts: developing a urinary marker for hypoxia.

  Cancer research 20050715

• Accumulation of hypoxia-inducible factor-1alpha is limited by transcription-dependent depletion.

  Oncogene 20050714

• A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.

  Cancer chemotherapy and pharmacology 20050701

• Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy.

  Neuro-oncology 20050701

• Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines.

  Investigational new drugs 20050601

• Chronic lymphocytic leukemia: a niche for flavopiridol?

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050601

• Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050601

• A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050515

• Drugging cell cycle kinases in cancer therapy.

  Current drug targets 20050501

• Flavopiridol sensitivity of cancer cells isolated from ascites and pleural fluids.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050501

• Cooperation between Cdk4 and p27kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity.

  Cancer research 20050501

• Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1-expressing cells to imatinib and geldanamycin.

  Cancer biology & therapy 20050401

• Recent progress in the discovery and development of cyclin-dependent kinase inhibitors.

  Expert opinion on investigational drugs 20050401

• [A novel small molecule cyclin-dependent kinase inhibitor flavopiridol in cancer therapy].

  Zhonghua yi xue za zhi 20050330

• Flavopiridol reduces malignant transformation of the esophageal mucosa in p27 knockout mice.

  Oncogene 20050303

• Flavopiridol blocks integrin-mediated survival in dormant breast cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050301

• Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells.

  Breast cancer research and treatment 20050301

• Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody.

  Blood 20050201

• Blockage of cyclin cdk's, PKC and phosphoinositol 3-kinase pathways leads to augmentation of apoptosis in drug-resistant leukemia cells: evidence for interactive effects of flavopiridol, LY 294002, roscovitine,wortmannin and UCN-01.

  Anticancer research 20050101

• Inhibition of multiple pathways accounts for the antiapoptotic effects of flavopiridol on potassium withdrawal-induced apoptosis in neurons.

  Journal of molecular neuroscience : MN 20050101

• New concepts in the treatment of acute myeloid malignancies: selected pathways for targeted therapy.

  Journal of biological regulators and homeostatic agents 20050101

• Inhibitors of cyclin-dependent kinase modulators for cancer therapy.

  Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques 20050101

• Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo.

  Anticancer research 20050101

• Induction of apoptosis by flavopiridol in human neuroblastoma cells is enhanced under hypoxia and associated with N-myc proto-oncogene down-regulation.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041215

• Cyclooxygenase-2 activity contributes to neuronal expression of cyclin D1 after anoxia/ischemia in vitro and in vivo.

  Brain research. Molecular brain research 20041206

• Flavopiridol, an inhibitor of transcription: implications, problems and solutions.

  Cell cycle (Georgetown, Tex.) 20041201

• E2F4 deficiency promotes drug-induced apoptosis.

  Cancer biology & therapy 20041201

• The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.

  Molecular cancer therapeutics 20041201

• Molecular models of cyclin-dependent kinase 1 complexed with inhibitors.

  Biochemical and biophysical research communications 20041112

• Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.

  Leukemia 20041101

• Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.

  Molecular pharmacology 20041001

• Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma.

  Investigational new drugs 20040801

• Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040801

• Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040801

• Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.

  Blood 20040715

• Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radioresponse.

  International journal of radiation oncology, biology, physics 20040715

• Transcriptional signature of flavopiridol-induced tumor cell death.

  Molecular cancer therapeutics 20040701

• Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: what's in a name?

  Molecular cancer therapeutics 20040701

• Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040615

• Neutropenic enterocolitis (typhilitis) associated with docetaxel therapy in a patient with non-small-cell lung cancer: case report and review of literature.

  Lung cancer (Amsterdam, Netherlands) 20040601

• Binding of the potential antitumour agent indirubin-5-sulphonate at the inhibitor site of rabbit muscle glycogen phosphorylase b. Comparison with ligand binding to pCDK2-cyclin A complex.

  European journal of biochemistry 20040601

• Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity.

  Anti-cancer drugs 20040601

• Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.

  Cancer research 20040515

• Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor.

  Cancer research 20040515

• Growth inhibition and induction of apoptosis by flavopiridol in rat lung adenocarcinoma, osteosarcoma and malignant fibrous histiocytoma cell lines.

  Oncology reports 20040501

• Enhancement of radiation effects by combined docetaxel and flavopiridol treatment in lung cancer cells.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20040501

• Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gammaH2AX foci.

  Molecular cancer therapeutics 20040401

• Combining flavopiridol with various signal transduction inhibitors.

  Oncology reports 20040301

• Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol.

  Molecular pharmacology 20040301

• Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040301

• Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9.

  The Journal of biological chemistry 20040206

• Inhibition of cell cycle pathway by flavopiridol promotes survival of cerebellar granule cells after an excitotoxic treatment.

  The Journal of pharmacology and experimental therapeutics 20040201

• Flavopiridol: where do we stand in chronic lymphocytic leukemia?

  Leukemia 20040201

• Flavopiridol inhibits the growth of GL261 gliomas in vivo: implications for malignant glioma therapy.

  Cell cycle (Georgetown, Tex.) 20040201

• A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040201

• Coordination of transcription, RNA processing, and surveillance by P-TEFb kinase on heat shock genes.

  Molecular cell 20040116

• A novel approach to develop anti-HIV drugs: adapting non-nucleoside anticancer chemotherapeutics.

  Antiviral research 20040101

• Cell-cycle targeted therapies.

  The Lancet. Oncology 20040101

• Flavopiridol as a radio-sensitizer for esophageal cancer cell lines.

  Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus 20040101

• Gemcitabine-induced apoptosis in a drug-resistant mouse leukemia L1210 cell line that does not express p53.

  Advances in enzyme regulation 20040101

• In vitro cell growth pharmacodynamic studies: a new nonparametric approach to determining the relative importance of drug concentration and treatment time.

  Cancer chemotherapy and pharmacology 20031201

• Flavopiridol downregulates the expression of both the inducible NO synthase and p27(kip1) in malignant cells from B-cell chronic lymphocytic leukemia.

  Leukemia 20031201

• The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20031201

• The role of hepatic Mrp2 in the interaction of flavopiridol and bilirubin: impact on therapy.

  International journal of clinical pharmacology and therapeutics 20031201

• The inducible NO synthase is downregulated during apoptosis of malignant cells from B-cell chronic lymphocytic leukemia induced by flavopiridol and polyphenols.

  Annals of the New York Academy of Sciences 20031201

• Inhibition of CDKs: a strategy for preventing kainic acid-induced apoptosis in neurons.

  Annals of the New York Academy of Sciences 20031201

• Acquired cellular resistance to flavopiridol in a human colon carcinoma cell line involves up-regulation of the telomerase catalytic subunit and telomere elongation. Sensitivity of resistant cells to combination treatment with a telomerase inhibitor.

  Molecular pharmacology 20031101

• Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity.

  Cancer research 20031101

• Biliary excretion of flavopiridol and its glucuronides in the isolated perfused rat liver: role of multidrug resistance protein 2 (Mrp2).

  Life sciences 20031017

• Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.

  Oncogene 20031016

• Neuroprotective action of flavopiridol, a cyclin-dependent kinase inhibitor, in colchicine-induced apoptosis.

  Neuropharmacology 20031001

• Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs.

  The Journal of pharmacology and experimental therapeutics 20031001

• Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.

  The Annals of pharmacotherapy 20031001

• Flavopiridol potently induces small cell lung cancer apoptosis during S phase in a manner that involves early mitochondrial dysfunction.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20031001

• Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030815

• Phase II study of flavopiridol in patients with advanced colorectal cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030801

• Cyclin-dependent kinase inhibitors.

  Current opinion in pharmacology 20030801

• A computational model of binding thermodynamics: the design of cyclin-dependent kinase 2 inhibitors.

  Journal of medicinal chemistry 20030717

• Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.

  Cancer chemotherapy and pharmacology 20030701

• Epidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancer.

  Cancer research 20030701

• Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells.

  Cancer research 20030615

• Commentary: effect of flavonoids on normal and leukemic cells.

  Leukemia research 20030601

• Flavonoid effects on normal and leukemic cells.

  Leukemia research 20030601

• The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.

  Melanoma research 20030601

• Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells.

  Molecular cancer therapeutics 20030601

• Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030501

• Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway.

  The Journal of thoracic and cardiovascular surgery 20030501

• The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.

  Cancer research 20030415

• Amelioration of nephropathy in mice expressing HIV-1 genes by the cyclin-dependent kinase inhibitor flavopiridol.

  The Journal of antimicrobial chemotherapy 20030401

• Cyclin-dependent kinase activity is required for apoptotic death but not inclusion formation in cortical neurons after proteasomal inhibition.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20030215

• Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines.

  Cancer research 20030201

• Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms.

  Anti-cancer drugs 20030201

• Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030201

• Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway.

  Molecular cancer therapeutics 20030201

• Flavopiridol induces apoptosis in B-cell chronic lymphocytic leukaemia cells through a p38 and ERK MAP kinase-dependent mechanism.

  Leukemia & lymphoma 20030201

• Flavopiridol, a cyclin dependent kinase (CDK) inhibitor, induces apoptosis by regulating Bcl-x in oral cancer cells.

  Oral oncology 20030101

• Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis.

  Cancer research 20030101

• Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis.

  Cancer research 20030101

• Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1.

  Molecular cancer therapeutics 20030101

• Protein kinase C-dependent activation of the tumor necrosis factor receptor-mediated extrinsic cell death pathway underlies enhanced apoptosis in human myeloid leukemia cells exposed to bryostatin 1 and flavopiridol.

  Molecular cancer therapeutics 20030101

• Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030101

• Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studies.

  Current medicinal chemistry. Anti-cancer agents 20030101

• Leukemic and non-leukemic lymphocytes from patients with Li Fraumeni syndrome demonstrate loss of p53 function, Bcl-2 family dysregulation and intrinsic resistance to conventional chemotherapeutic drugs but not flavopiridol.

  Cell cycle (Georgetown, Tex.) 20030101

• Flavopiridol induces mitochondrial-mediated apoptosis in murine glioma GL261 cells via release of cytochrome c and apoptosis inducing factor.

  Cell cycle (Georgetown, Tex.) 20030101

• Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.

  Annals of oncology : official journal of the European Society for Medical Oncology 20030101

• c-Myc oncoprotein: cell cycle-related events and new therapeutic challenges in cancer and cardiovascular diseases.

  Cell cycle (Georgetown, Tex.) 20030101

• Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol.

  Cancer chemotherapy and pharmacology 20021201

• The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20021101

• Zebrafish: a preclinical model for drug screening.

  Assay and drug development technologies 20021101

• Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20021001

• Cyclin-dependent kinases as new targets for the prevention and treatment of cancer.

  Hematology/oncology clinics of North America 20021001

• A high-performance liquid chromatography method using ultraviolet detection for the quantitation of flavopiridol from human plasma.

  Biomedical chromatography : BMC 20020901

• Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020901

• Clinical trials referral resource. Flavopiridol.

  Oncology (Williston Park, N.Y.) 20020901

• Hematologic malignancies: new developments and future treatments.

  Seminars in oncology 20020801

• Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells.

  Cancer research 20020715

• Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).

  Leukemia 20020701

• Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.

  Molecular cancer therapeutics 20020701

• Flavopiridol inhibits vascular endothelial growth factor production induced by hypoxia or picolinic acid in human neuroblastoma.

  International journal of cancer 20020610

• Synergistic induction of apoptosis in human myeloid leukemia cells by phorbol 12-myristate 13-acetate and flavopiridol proceeds via activation of both the intrinsic and tumor necrosis factor-mediated extrinsic cell death pathways.

  Molecular pharmacology 20020601

• Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy.

  Seminars in oncology 20020601

• Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity.

  The Journal of pharmacology and experimental therapeutics 20020501

• Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.

  The Annals of pharmacotherapy 20020501

• Evidence for CRK3 participation in the cell division cycle of Trypanosoma cruzi.

  Molecular and biochemical parasitology 20020501

• In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes.

  Pharmaceutical research 20020501

• Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol.

  Biochemical and biophysical research communications 20020426

• Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics.

  Journal of medicinal chemistry 20020425

• Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol.

  Cancer research 20020415

• Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020415

• Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma.

  Leukemia & lymphoma 20020401

• Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase.

  Cancer research 20020315

• Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol.

  Leukemia research 20020301

• Prevalent loss of mitotic spindle checkpoint in adult T-cell leukemia confers resistance to microtubule inhibitors.

  The Journal of biological chemistry 20020215

• Inhibition of cyclin-dependent kinases improves CA1 neuronal survival and behavioral performance after global ischemia in the rat.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20020201

• The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells.

  Molecular cancer therapeutics 20020201

• The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01.

  The oncologist 20020101

• Loss of the Bcl-2 phosphorylation loop domain is required to protect human myeloid leukemia cells from flavopiridol-mediated mitochondrial damage and apoptosis.

  Cancer biology & therapy 20020101

• [Report on 93rd AACR].

  Bulletin du cancer 20020101

• CDK inhibitors: cell cycle arrest versus apoptosis.

  Cell cycle (Georgetown, Tex.) 20020101

• Flavopiridol inversely affects p21(WAF1/CIP1) and p53 and protects p21-sensitive cells from paclitaxel.

  Cancer biology & therapy 20020101

• Role reversal for anticancer agents.

  Cancer biology & therapy 20020101

• Suppression of HIV-1 expression by inhibitors of cyclin-dependent kinases promotes differentiation of infected podocytes.

  Journal of the American Society of Nephrology : JASN 20011201

• Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20011201

• Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol.

  Molecular pharmacology 20011101

• Microtubule-targeting drugs induce bcl-2 phosphorylation and association with Pin1.

  Neoplasia (New York, N.Y.) 20011101

• Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo.

  The Journal of biological chemistry 20010824

• Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010801

• Flavopiridol. National Cancer Institute.

  Current opinion in investigational drugs (London, England : 2000) 20010801

• The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway.

  Cell death and differentiation 20010701

• Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia.

  British journal of haematology 20010701

• A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010601

• Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells.

  Leukemia 20010601

• Mechanisms of action of flavopiridol.

  Critical reviews in oncology/hematology 20010501

• Characterization of autoantibodies against uridine-diphosphate glucuronosyltransferase in patients with inflammatory liver diseases.

  Hepatology (Baltimore, Md.) 20010501

• Effect of P-glycoprotein on flavopiridol sensitivity.

  British journal of cancer 20010501

• The CRK3 protein kinase is essential for cell cycle progression of Leishmania mexicana.

  Molecular and biochemical parasitology 20010406

• In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: involvement of UDP-glucuronosyltransferases 1A1 and 1A9.

  Drug metabolism and disposition: the biological fate of chemicals 20010401

• Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010401

• [CDK inhibitors for therapy of cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20010401

• Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity.

  Cancer research 20010315

• The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.

  Cancer research 20010315

• Characterization of the Trypanosoma cruzi Cdc2p-related protein kinase 1 and identification of three novel associating cyclins.

  Molecular and biochemical parasitology 20010301

• The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase.

  Archives of biochemistry and biophysics 20010215

• Possible mechanisms of diarrheal side effects associated with the use of a novel chemotherapeutic agent, flavopiridol.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010201

• Strategies to circumvent SV40 oncoprotein expression in malignant pleural mesotheliomas.

  Seminars in cancer biology 20010201

• Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?

  The Journal of biological chemistry 20010105

• Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010101

• Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies.

  Leukemia 20010101

• Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genes.

  Blood cells, molecules & diseases 20010101

• Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol.

  Genome biology 20010101

• Bcl-2 independence of flavopiridol-induced apoptosis. Mitochondrial depolarization in the absence of cytochrome c release.

  The Journal of biological chemistry 20001013

• Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol.

  International journal of oncology 20001001

• Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia.

  Blood 20000715

• Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines.

  Clinical cancer research : an official journal of the American Association for Cancer Research 19991001

• Flavopiridol inhibits smooth muscle cell proliferation in vitro and neointimal formation In vivo after carotid injury in the rat.

  Circulation 19990810

• Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 19990701

• Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases.

  Cancer research 19990601

• Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.

  Blood 19981115

• Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.

  The Journal of clinical investigation 19981101

• Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 19981101

• Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.

  Science (New York, N.Y.) 19980724

• Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts.

  Blood 19980401

• Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol.

  Blood 19980115

• Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

  Cancer research 19960701

• Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275.

  Biochemical and biophysical research communications 19940615

• Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity.

  Biochemical pharmacology 19931117

• Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275.

  Journal of the National Cancer Institute 19921118